Company record · updated August 5, 2026
Dragonfly Therapeutics Inc: 1 valuation observation from SEC filings
Every row below names the filing it came from. Coverage for this company runs August 31, 2025 to August 31, 2025.
1observations
1source filings
1verified rows
2025-08-31most recent as-of date
Source rails for this company: N-PORT fund mark (1).
Reported by 1 filer: Fidelity Series Growth Company Fund.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2025-08-31 | price per share | 33.98 USD | Fidelity Series Growth Company Fund | VERIFIED | valUSD 4285319.74 / balance 126113.0 [pp] | 000003540225001412 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.